KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Gains from Investment Securities (2016 - 2024)

Historic Gains from Investment Securities for Nektar Therapeutics (NKTR) over the last 15 years, with Q4 2024 value amounting to -$7.6 million.

  • Nektar Therapeutics' Gains from Investment Securities rose 1947.05% to -$7.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $76000.0, marking a year-over-year decrease of 9713.86%. This contributed to the annual value of $76000.0 for FY2024, which is 9713.86% down from last year.
  • Nektar Therapeutics' Gains from Investment Securities amounted to -$7.6 million in Q4 2024, which was up 1947.05% from $2.1 million recorded in Q3 2024.
  • Nektar Therapeutics' 5-year Gains from Investment Securities high stood at $6.7 million for Q4 2021, and its period low was -$9.5 million during Q4 2023.
  • Its 5-year average for Gains from Investment Securities is $544000.0, with a median of $2.1 million in 2024.
  • Examining YoY changes over the last 5 years, Nektar Therapeutics' Gains from Investment Securities showed a top increase of 77170.14% in 2023 and a maximum decrease of 42095.46% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Gains from Investment Securities (Quarter) stood at $2.1 million in 2020, then surged by 215.71% to $6.7 million in 2021, then crashed by 56.13% to $3.0 million in 2022, then plummeted by 420.95% to -$9.5 million in 2023, then increased by 19.47% to -$7.6 million in 2024.
  • Its last three reported values are -$7.6 million in Q4 2024, $2.1 million for Q3 2024, and $2.6 million during Q2 2024.